Thesis icon

Thesis

Translational development of MyD88 as a biomarker for selecting patients with lymphoma responsive to histone deacetylase inhibitors

Abstract:
Histone deacetylase inhibitors (HDIs) are promising new agents for the treatment of haematological malignancy including lymphoma. MyD88 expression and secretion of pro-inflammatory cytokines may contribute to the sensitization of cancer cells to HDI. Moreover, MyD88 may be a direct target for HDAC- and BRD- inhibitors. Therefore, both expression level of MyD88 and MyD88 mutation status could serve as potential biomarkers for HDI sensitivity in patient selection.

Actions


Access Document


Files:

Authors


Semira Sheikh More by this author

Contributors

Department:
University of Oxford
Role:
Supervisor
More from this funder
Funding agency for:
Project
Type of award:
DPhil
Level of award:
Doctoral
Awarding institution:
University of Oxford

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP